서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 14 of 14

Issue DateTitle / Author(s) / CitationFileAltmetrics
2010-07
Replication of Lung Cancer Susceptibility Loci at Chromosomes 15q25, 5p15, and 6p21: A Pooled Analysis From the International Lung Cancer Consortium

Truong, Therese; Hung, Rayjean J.; Amos, Christopher I.; Wu, Xifeng; Rosenberger, Albert; Illig, Thomas; Risch, Angela; Kaaks, Rudolph; Jiang, Ruoxiang; Seow, Adeline; Wenzlaff, Angie; Schwartz, Ann G.; Tajima, Kazuo; Matsuo, Keitaro; Kelsey, Karl T.; Hansen, Helen; Wrensch, Margaret; Wiencke, John K.; Zhang, Zuo-Feng; Stefansson, Kari; Rafnar, Thorunn; Ignacio Mayordomo, Jose; Isla, Dolores; Kiemeney, Lambertus A.; van der Heijden, Henricus F. M.; Haugen, Aage; Zienolddiny, Shanbeh; McKay, James D.; Liu, Geoffrey; McLaughlin, John; Xue, Xiaoyan; Teare, M. Dawn; Bouchardy, Christine; Benhamou, Simone; Le Marchand, Loic; Brenner, Hermann; Spitz, Margaret R.; Brennan, Paul; Mueller, Heiko; Rennert, Gad; Lejbkowicz, Flavio; Andrew, Angeline S.; Duell, Eric J.; Hong, Yun-Chul; Kim, Jin Hee; Chang, Shen-Chih; Gallagher, Carla J.; Muscat, Joshua E.; Lazarus, Philip; Wolf, Jurgen; Stoelben, Erich; Nuernberg, Peter; Staratschek-Jox, Andrea; Ying, Chen; Yang, Ping; Dienemann, Hendrik; Wichmann, H. -Erich; Sauter, Wiebke; Bickeboeller, Heike

JOURNAL OF THE NATIONAL CANCER INSTITUTE; Vol.102 13; 959-971

DOI
2014-03
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
DOI
2016-04
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
DOI
2020-11
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
DOI
2021-08
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer
DOI
2022-07
Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial
DOI
2022-12
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)
DOI
2022-12
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer
DOI
2023-04
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
DOI
2023-05
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer
DOI
2023-12
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
DOI
2024
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer
DOI
2024-06
Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK plus non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.
DOI
2024-10
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
DOI
1